Qinglin Pu

Qinglin Pu

Auto-generated profile, based on publicly available information

Qinglin Pu

Departments of Discovery Chemistry, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2020 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
QPQinglin Pu
Qinglin Pu
HZHongjun Zhang
Hongjun Zhang
LGLiangqin Guo
Liangqin Guo
MCMangeng Cheng
Mangeng Cheng
ADAmy C. Doty
Amy C. Doty
YHYongxin Han
Yongxin Han

26 February 2021 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
DLDerun Li
Derun Li
YDYongqi Deng
Yongqi Deng
AAAbdelghani Achab
Abdelghani Achab
IBIndu Bharathan
Indu Bharathan
BHBrett Andrew Hopkins
Brett Andrew Hopkins
YHYongxin Han
Yongxin Han

16 July 2021 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Open access
MLMin Lu
Min Lu
HZHongjun Zhang
Hongjun Zhang
DLDerun Li
Derun Li
MCMatthew Childers
Matthew Childers
QPQinglin Pu
Qinglin Pu
CFChristian Fischer
Christian Fischer
Recent data suggest that the inhibition of arginase (ARG) has therapeutic potential for the treatment of a number of indications ranging from pulmonary and vascular disease to cancer. Thus, high demand exists for selective small molecule ARG inhibitors with favorable druglike properties and good oral bioavailability. In light of the significant challenges associated with the unique physicochemical properties of previously disclosed ARG inhibitors, we use structure-based drug design combined with a focused optimization strategy to discover a class of boronic acids featuring a privileged proline scaffold with superior potency and oral bioavailability. These compounds, exemplified by inhibitors 4a, 18, and 27, demonstrated a favorable overall profile, and 4a was well tolerated following multiple days of dosing at concentrations that exceed those required for serum arginase inhibition and concomitant arginine elevation in a syngeneic mouse carcinoma model.

13 October 2021 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
DLDerun Li
Derun Li
HZHongjun Zhang
Hongjun Zhang
TLThomas W. Lyons
Thomas W. Lyons
MLMin Lu
Min Lu
AAAbdelghani Achab
Abdelghani Achab
CFChristian Fischer
Christian Fischer

3 March 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DLDerun Li
Derun Li
DSDavid L. Sloman
David L. Sloman
AAAbdelghani Achab
Abdelghani Achab
HZHua Zhou
Hua Zhou
MMMeredeth A. McGowan
Meredeth A. McGowan
YHYongxin Han
Yongxin Han

18 August 2021 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
BHBrett Hopkins
Brett Hopkins
HZHongjun Zhang
Hongjun Zhang
IBIndu Bharathan
Indu Bharathan
DLDerun Li
Derun Li
QPQinglin Pu
Qinglin Pu
YHYongxin Han
Yongxin Han